Clinical Trials

Clinical Trials Conducted by WCRI

 

Topical Gel for acne vulgaris,
Dermira January 2015 (phase II)

 

Follow-up study on filiation between primary and secondary acne lesions,
March 2015 (Prospective scientific research study)

 

Oral therapy for moderate to severe atopic dermatitis,
Dignity, Jan 2015 (phase II)

 

Injectable biologic therapy for moderate to severe atopic dermatitis,
MedImmune, Jan 2015 (phase IIb)

 

Injectable biologic therapy for moderate to severe atopic dermatitis,
Regeneron, Nov 2014 (phase III)

 

Aczone gel versus vehicle control for acne vulgaris,
Allergan February 2014

 

Topical Gel for rosacea,
Dermira October 2013

 

Topical Gel for acne vulgaris,
Dermira October 2013

 

Botox & vehicle for glabellar lines (facial wrinkles),
Allergan September 2013

 

Ixekizumab for psoriasis,
Eli Lilly, Aug 2013

 

Humira for psoriasis and vascular effects,
Abbott and Innovaderm, Feb 2013

 

Topical gel for severe acne,
Galderma, Feb 2013

 

Topical gel for moderate acne,
Galderma, Dec 2012

 

Oral medication for psoriasis,
Incyte, March 2012

 

Pill treatment for severe acne,
Galderma, Oct. 2011

 

Topical gel treatment for rosacea,
Galderma, May 2011

 

Enbrel for moderate-severe psoriasis,
Amgen, Feb 2011

 

Oral medication for moderate-severe psoriasis, 
Pfizer, June 2010

 

Oral medication for moderate-severe psoriasis, 
Celgene, July 2010

 

Response of palmoplantar pustulosis and palmoplantar pustular psoriasis to a biologic,
Innovaderm, Apr 2010

 

Case-finding for psoriatic arthritis in a psoriasis cohort,
Pfizer, Nov 2010

 

Oral therapy for moderate-severe psoriasis vulgaris,
Celgene, Dec. 2010

 

Biologic therapy for psoriatic arthritis,
Janssen-Ortho, Feb. 2010 (phase III)

 

Topical therapy for atopic dermatitis,
Welichem Pharma, Mar 2010 (phase II)

 

Topical therapy for atopic dermatitis,
Leo Pharma, Jan 2010 (phase II)

 

Topical therapy for onychomycosis,
Dow Pharma, Jan 2010 (phase III)

 

Oral retinoid therapy for severe acne vulgaris,
Cipher Pharma, Dec. 2009 (phase III)

 

Photodynamic therapy for acne vulgaris,
Photocure, August 2009 (phase IIb)

 

Oral therapy for moderate to severe psoriasis,
Pfizer, Jan 2009 (phase IIb)

 

Topical therapy for maintenance of improvement in acne after oral antibiotics,
Galderma, Oct. 2008 (phase III)

 

Topical gel therapy for facial acne vulgaris,
Stiefel Laboratories, April 2008 (phase III)

 

Topical therapy for truncal psoriasis,
Leo Laboratories, Feb. 2008 (phase III)

 

Topical therapy for facial psoriasis,
Leo Laboratories, Feb. 2008 (phase III)

 

Biologic therapy for moderate to severe psoriasis,
Abbott Laboratories, Jan 2008 (phase III)

 

Biologic therapy for moderate to severe psoriasis with active comparator,
Centocor, June 2007 (phase III).

 

Topical therapy for toenail onychomycosis,
Novartis, Mar. 2007 (phase III).

 

Oral therapy for toenail onychomycosis,
Barrier Therapeutics, Feb. 2007 (phase III).

 

Topical therapy for atopic eczema,
Leo laboratories, Feb. 2007 (phase II).

 

Topical facial cleansing wash for moderate facial acne,
Stiefel, November 2006 (phase IV).

 

Topical combination therapy for moderate facial acne,
Galderma, June 2006 (phase III).

 

Injectable biologic for moderate-severe psoriasis,
Serono, June 2006 (phase IV).

 

Topical calcineurin inhibitor for psoriasis – long-term safety,
March 2006 (phase III).

 

Injectable biologic for moderate-severe psoriasis,
Amgen-Wyeth, March 2006 (phase IV).

 

Comparison of 2 topical washes for mild-moderate facial acne,
Stiefel Canada, March 2006 (phase III).

 

Injectable biologic for moderate-severe plaque psoriasis,
Centocor Feb. 2006 (phase III).

 

Injectable biologic for psoriatic arthritis,
Centocor Dec 2005 (phase II).

 

National Coordinating Investigator, Topical treatment for moderate to severe scalp psoriasis,
Leo Pharma, Sep 2005 (phase III).

 

Topical imiquimod or vehicle following cryotherapy for actinic keratoses, Investigator-Initiated Trial,
3M Pharmaceuticals, Mar 2005 (phase IV).

 

Topical therapy for severe scalp psoriasis,
Leo Pharma, Feb 2005 (phase III).

 

Oral treatment for moderate to severe plaque psoriasis,
Isotechnika, Dec. 2005 – ongoing phase III).

 

Biologic therapy for moderate to severe plaque psoriasis with a TNF-blocking agent,
Serono, Sep. 2004 – ongoing (phase III).

 

Oral treatment for severe hand dermatitis,
Basilea Therapeutics, Aug 2004 (phase III).

 

Oral treatment for tinea capitis,
Novartis Canada, July 2004 (phase IV).

 

Topical treatment for mild-moderate hand dermatitis,
Novartis Canada, July 2004 (phase IV).

 

Open-label extension study of an intramuscular biologic treatment for moderate-severe psoriasis vulgaris,
Biogen Canada, Mar. 2004 (phase IV).

 

Topical cream for atopic dermatitis,
Fujisawa, Jan. 2004 (phase III).

 

Oral treatment for herpes labialis,
Novartis Canada, Nov. 2003 (phase III).

 

Topical treatment for palmoplantar pustulosis,
LeoLaboratories, Oct. 2003 (phase IV).

 

Intravenous injection of a biological agent for moderate- severe plaque psoriasis,
Biogen, Sept. 2003 (phase III).

 

Biological injection treatment for severe unresponsive psoriasis vulgaris,
Serono, Sept. 2003 – May 2005 (phase III).

 

Topical cream for treatment of moderate acne vulgaris,
Novartis, Dec. 2002 – Sept 2003 (phase III).

 

Topical cream for treatment of moderate acne vulgaris,
Atrix Laboratories, Jan 2003 (phase III).

 

Canadian Acne Epidemiological Project,
DermNet Database Inc, Sept 2002 – ongoing.

 

Intramuscular therapy for stable plaque psoriasis: extension study III,
Biogen, (phase III).

 

Long-term safety study of Dovobet for plaque psoriasis,
Leo Laboratories, May 2002 (phase IV).

 

Topical treatment for atopic eczema,
Novartis, Jan. 2002 (phase IV).

 

Oral retinoid treatment for severe psoriasis vulgaris,
Allergan, December 2001 (phase II/III).

 

Topical therapy for atopic eczema,
Leo Laboratiories, November 2001 (phase II/III).

 

Topical therapy for atopic eczema,
Fujisawa Canada, October 2001 (phase IV).

 

Intramuscular therapy for stable plaque psoriasis: extension study II,
Biogen, November 2001 (phase III).

 

Topical therapy for plaque psoriasis vulgaris,
Leo Pharma, Mar 2001-Oct 2001 (phase III).

 

Pharmacokinetics of an oral retinoid for acne,
Roche, Sept-Dec 2001 (phase II).

 

Intramuscular therapy for stable plaque psoriasis: extension study,
Biogen, November 2000 (phase III).

 

Topical therapy for atopic eczema,
Fujisawa Canada, November 2000 (phase III).

 

Systemic therapy for severe nodulocystic acne,
Allergan, November 2000 (phase II).

 

Topical treatment for rosacea,
Stieffel Canada, July 2000, (phase III).

 

Intramuscular therapy for stable plaque psoriasis,
Biogen, May 2000 (phase III).

 

Topical treatment for atopic eczema in infants,
Novartis, Feb. 2000 (phase III).

 

Topical therapy for stable plaque psoriasis,
Leo Laboratories, Jan.-May 2000.

 

Tazorac in Comedonal Acne,
Allergan Canada, Sept.-Dec. 1999 (phase IV).

 

Topical treatment for atopic eczema in pediatric patients,
Novartis, Sep. 99-ongoing (phase III).

 

Systemic treatment for recurrent Herpes Genitalis,
Glaxo Wellcome, Oct 98-Dec 1999 (phase IV).

 

Treatment for venous leg ulcers,
Novartis, Oct. 98-Jan 2000 (phase III).

 

Propecia in Androgenetic Alopecia,
Merck Canada, Oct. 98-Jan 99 (phase IV).

 

Topical treatment for male pattern androgenetic alopecia,
Leo Laboratories, Oct. 98 – June 99 (phase III).

 

Topical treatment for rosacea,
Stiefel Canada, Dec. 97-Apr 98 (phase III).

top